CTSO
CytoSorbents Corporation
$0.50
-$0.04(-8.16%)
52
Overall
60
Value
50
Tech
47
Quality
Market Cap
$45.19M
Volume
190.00K
52W Range
$0.50 - $1.39
Target Price
$5.56
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $9.5M | $15.2M | $22.5M | $24.9M | $41.0M | $43.2M | $34.7M | $31.1M | $35.6M | $37.1M | ||
| Total Revenue | $8.2M | $15.2M | $22.5M | $24.9M | $41.0M | $43.2M | $29.4M | $31.1M | $35.6M | $37.1M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-4.0M | $-5.5M | $-7.5M | $7.4M | $11.1M | $11.0M | $14.0M | $9.1M | $10.7M | $10.6M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $5.6M | $9.6M | $15.0M | $17.6M | $28.4M | $29.1M | $15.4M | $22.0M | $24.9M | $26.5M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-17.1M | $-19.5M | $-30.6M | $36.6M | $40.3M | $54.9M | $46.9M | $53.9M | $41.3M | $41.2M | ||
| Research & Development | $4.8M | $3.2M | $7.7M | $12.1M | $8.8M | $16.4M | $15.1M | $15.7M | -- | -- | ||
| Research Expense | $4.8M | $3.2M | $7.7M | $12.1M | $8.8M | $16.4M | $15.1M | $15.7M | -- | -- | ||
| Selling, General & Administrative | $12.3M | $16.3M | $22.9M | $24.5M | $31.5M | $38.5M | $37.1M | $38.3M | $33.7M | $35.6M | ||
| Selling & Marketing Expenses | $11.1M | $14.9M | $20.9M | $314.0K | $285.0K | $615.0K | $582.0K | $252.7K | $335.3K | -- | ||
| General & Administrative Expenses | $1.2M | $1.3M | $2.0M | $24.5M | $31.5M | $38.5M | $37.1M | $38.3M | $33.7M | $35.6M | ||
| Promotion & Advertising | $-173.0K | $-162.0K | $-212.0K | $314.0K | $285.0K | $615.0K | $582.0K | -- | -- | -- | ||
| Salaries & Wages | $-2.8M | $-3.3M | $-4.4M | $315.0K | $914.0K | $1.1M | -- | $4.2M | $3.8M | $2.8M | ||
| Depreciation & Amortization | $-126.1K | $-177.8K | $-329.5K | $495.7K | $553.9K | $571.2K | $688.6K | $1.5M | $1.6M | -- | ||
| Depreciation & Amortization | $-126.1K | $-177.8K | $-329.5K | $495.7K | $553.9K | $571.2K | $688.6K | -- | -- | -- | ||
| Amortization | $-35.5K | $-40.5K | $-61.1K | $85.8K | $106.8K | $160.4K | $194.1K | $434.8K | $469.2K | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-11.5M | $-25.0M | $-38.1M | $-19.0M | $-10.4M | $-22.7M | $-31.5M | $-31.9M | $-16.5M | $-14.7M | ||
| EBITDA | $-11.9M | $-8.8M | $-17.3M | $-19.7M | $-9.7M | $-21.6M | $-30.4M | $-27.9M | $-19.2M | $-3.7M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | $1.2M | -- | -- | -- | $1.4M | $2.6M | ||
| Interest Income Operating | -- | $13.4M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Intinc | $-231.8K | $-749.1K | $-1.5M | $-1.0M | $-1.2M | $28.0K | $132.6K | $-157.9K | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-231.8K | $-749.1K | $-1.5M | $-1.0M | $-1.2M | $28.0K | $132.6K | $-157.9K | $-1.4M | $-2.6M | ||
| Other Income/Expense | $175.4K | $-1.8M | $-22.5M | -- | -- | -- | $-2.5M | $2.0M | -- | -- | ||
| Other Special Charges | $-175.4K | $13.4M | $22.5M | -- | -- | -- | $-67.3K | -- | -- | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $510.0K | ||
| Special Income Charges | -- | -- | $637.0K | -- | -- | -- | -- | $-4.3M | $-3.2M | $-510.0K | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-12.1M | $-9.1M | $-17.8M | $-20.4M | $-10.4M | $-22.7M | $-31.5M | $-29.9M | $-21.0M | $-6.0M | ||
| Pre-Tax Income | $-12.1M | $-9.1M | $-17.8M | $-20.4M | $-9.0M | $-25.3M | $-33.9M | $-30.1M | $-22.4M | $-8.6M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-318.6K | $-676.7K | $-619.5K | $-1.1M | $-1.1M | $-736.0K | $-1.1M | $-813.7K | $-1.7M | $-401.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-11.8M | $-8.5M | $-17.2M | $-19.3M | $-7.8M | $-24.6M | $-32.8M | $-29.2M | $-20.7M | $-8.2M | ||
| Net Income (Continuing Operations) | $-11.8M | $-8.5M | $-17.2M | $-19.3M | $-7.8M | $-24.6M | $-32.8M | $-29.2M | $-20.7M | $-8.2M | ||
| Net Income (Discontinued Operations) | $-11.8M | $-8.5M | $-17.2M | $-19.3M | $-7.8M | $-24.6M | $-32.8M | $-29.2M | $-20.7M | $-8.2M | ||
| Net Income (Common Stockholders) | $-11.8M | $-8.8M | $-17.2M | $-19.3M | $-7.8M | $-24.6M | $-32.8M | $-29.2M | $-20.7M | $-8.2M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-8.5M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-21.0M | $-25.0M | $-38.1M | $43.9M | $51.4M | $65.9M | $60.9M | $63.0M | $52.0M | $51.8M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $25.4M | $27.6M | $30.7M | $32.3M | $38.8M | $43.4M | $43.6M | $44.7M | $54.4M | $62.2M | ||
| Average Shares Outstanding (Diluted) | $25.4M | $26.4M | $30.7M | $32.3M | $38.8M | $43.4M | $43.6M | $44.7M | $54.4M | $62.2M | ||
| Shares Outstanding | $25.5M | $29.5M | $31.9M | $35.1M | $43.3M | $43.5M | $43.7M | $54.3M | $62.5M | $62.7M | ||
| Basic EPS | -- | -- | -- | $-0.60 | $-0.20 | $-0.57 | $-0.75 | $-0.64 | $-0.38 | $-0.13 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-0.60 | $-0.20 | $-0.57 | $-0.75 | $-0.64 | $-0.38 | $-0.13 | ||
| Diluted EPS | $-0.47 | $-0.32 | $-0.56 | $-0.60 | $-0.20 | $-0.57 | $-0.75 | $-0.64 | $-0.38 | $-0.13 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-0.57 | $-0.75 | $-0.64 | $-0.38 | $-0.13 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | $335.7K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Acquired In Process Rn D Income | -- | $1.8M | $20.1M | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $1.2M | $1.3M | $2.0M | $24.5M | $31.5M | $38.5M | $37.1M | $38.3M | $33.7M | $35.6M | ||
| Otherunder Preferred Stock Dividend | -- | $335.7K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | -- | $335.7K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Realized Capital Gain | -- | -- | $2.3M | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $-473.0K | $-676.0K | $-805.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $11.1M | $14.9M | $20.9M | -- | -- | -- | -- | -- | -- | -- | ||
| Othspecchg | -- | -- | $-637.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | -- | -- | -- | $510.0K | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CTSO | $0.50 | -8.2% | 190.00K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get CytoSorbents Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW